Treatment Patterns and Outcomes in Patients Undergoing Percutaneous Coronary Intervention Treated With Prasugrel or Clopidogrel (from the Swedish Coronary Angiography and Angioplasty Registry [SCAAR])
In conclusion, in this real world population of patients who underwent urgent or elective PCI, prasugrel was used mainly in patients with ACS, while it was avoided in patients with characteristics indicating increased bleeding risk. Mortality and bleeding rates were lower with prasugrel than clopidogrel, probably because of patient selection.
Source: The American Journal of Cardiology - Category: Cardiology Authors: Peter Damman, Christoph Varenhorst, Sasha Koul, Peter Eriksson, David Erlinge, Bo Lagerqvist, Stefan K. James Tags: Coronary Artery Disease Source Type: research
More News: Angiography | Angioplasty | Bleeding | Cardiology | Clopidogrel | Coronary Angioplasty | Heart | Heart Attack | Hemorrhagic Stroke | Percutaneous Coronary Intervention | Plavix | Stroke | Study